tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

OCGN Stock Latest News

Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
Press ReleasesOcugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
3d ago
OCGN
Ocugen completes dosing in second cohort of Phase 1/2 GARDian trial for OCU410ST
PremiumThe Fly
Ocugen completes dosing in second cohort of Phase 1/2 GARDian trial for OCU410ST
3d ago
OCGN
Ocugen to begin dosing in Phase 3 liMeliGhT trial in Q2
PremiumThe Fly
Ocugen to begin dosing in Phase 3 liMeliGhT trial in Q2
3d ago
OCGN
Ocugen reports Q1 EPS (5c), consensus (6c)
PremiumThe Fly
Ocugen reports Q1 EPS (5c), consensus (6c)
3d ago
OCGN
Ocugen Provides Business Update with First Quarter 2024 Financial Results
PremiumPress Releases
Ocugen Provides Business Update with First Quarter 2024 Financial Results
3d ago
OCGN
Options Volatility and Implied Earnings Moves Today, May 14, 2024
PremiumMarket NewsOptions Volatility and Implied Earnings Moves Today, May 14, 2024
3d ago
HD
NU
Options Volatility and Implied Earnings Moves This Week, May 13 – May 16, 2024
PremiumMarket News
Options Volatility and Implied Earnings Moves This Week, May 13 – May 16, 2024
5d ago
DE
DT
Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
PremiumPress Releases
Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
7d ago
OCGN
Ocugen to Present at May 2024 Investor Conferences
PremiumPress Releases
Ocugen to Present at May 2024 Investor Conferences
7d ago
OCGN
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
14d ago
CCI
IEP
Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results
PremiumPress Releases
Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results
14d ago
OCGN
Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
PremiumPress Releases
Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
15d ago
OCGN
Ocugen Inc Lawsuits Dismissed by Pennsylvania Court
PremiumCompany AnnouncementsOcugen Inc Lawsuits Dismissed by Pennsylvania Court
18d ago
8K
OCGN
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
PremiumPress Releases
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
19d ago
OCGN
UPDATE — Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
PremiumPress Releases
UPDATE — Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
21d ago
OCGN
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
PremiumPress Releases
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
22d ago
OCGN
Ocugen price target raised to $5 from $4 at Chardan
PremiumThe Fly
Ocugen price target raised to $5 from $4 at Chardan
25d ago
OCGN
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
PremiumPress Releases
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
28d ago
OCGN
Ocugen announces dosing completion of Cohort 2 in OCU410 Phase 1/2 trial
PremiumThe Fly
Ocugen announces dosing completion of Cohort 2 in OCU410 Phase 1/2 trial
28d ago
OCGN
Ocugen files $175M mixed securities shelf
PremiumThe FlyOcugen files $175M mixed securities shelf
30d ago
OCGN
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
PremiumPress Releases
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
1M ago
OCGN
Ocugen announces CHMP of EMA reviewed Phase 3 study design for OCU400
PremiumThe Fly
Ocugen announces CHMP of EMA reviewed Phase 3 study design for OCU400
1M ago
OCGN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >